<DOC>
	<DOCNO>NCT03032419</DOCNO>
	<brief_summary>The trial phase III , non-inferiority , observer-blind , randomise , control , multicentre clinical trial 2 parallel group : IPV-Al SSI ( investigational vaccine ) IPV SSI ( reference vaccine )</brief_summary>
	<brief_title>Safety Immunogenicity Adjuvanted Reduced Dose Inactivated Polio Vaccine Given 6 , 10 , 14 Weeks 9 Months</brief_title>
	<detailed_description>In addition trial vaccine ( IPV-Al SSI IPV SSI ) , trial subject receive vaccination Philippine national childhood vaccination programme . The trial vaccine ( IPV-Al SSI IPV SSI ) administer RIGHT thigh , injectable childhood vaccine administer opposite ( LEFT ) thigh . There 6 trial visit : Visit 1 ( screening , 1st vaccination blood sample visit ) : write informed consent obtain . Information medical history , demographic concomitant medication collect , physical examination perform subject 's eligibility assess accord pre-specified in-/exclusion criterion . A pre-vaccination blood sample take polio antibody measurement , subject randomly allocate one 2 group vaccinate . If possible draw blood sample Visit 1 child continue trial . The subject observe immediate AEs Â½ hour vaccination . A diary , ruler thermometer hand parent record daily temperature injection site reaction , first 3 day vaccination resolve record AEs instruct trial staff . 2 day Visit 1 trial staff make telephone call parent ( ) /guardian ( ) clarify question regard AE record diary . Visit 2 ( 2nd vaccination visit ) , 28-42 day Visit 1 : contraindication review , 2nd vaccination give , diary collect AEs concomitant medication ( CMs ) record . A new diary hand . 2 day Visit 2 trial staff make telephone call parent ( ) /guardian ( ) clarify question regard AE record diary . Visit 3 ( 3rd vaccination visit ) , 28-42 day Visit 2 : contraindication review , 3rd vaccination give , diary collect AEs CMs record . A new diary hand . 2 day Visit 3 trial staff make telephone call parent ( ) /guardian ( ) clarify question regard AE record diary . Visit 4 ( blood sample visit ) , 28-42 day Visit 3 : blood sample polio antibody measurement take , diary collect , AEs CMs record . Visit 5 ( 4th vaccination blood sample visit ) , 9 month age ( +14 day ) : blood sample take polio antibody measurement , contraindication review , 4th vaccination give , AEs CMs record . A new diary hand . 2 day Visit 5 trial staff make telephone call parent ( ) /guardian ( ) clarify question regard AE record diary . Visit 6 ( blood sample end trial visit ) , 28-42 day Visit 5 : blood sample polio antibody measurement take , diary collect , AEs CMs record . The end trial form complete .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Infants 6 week age ( 3 +14 day ) date 1st vaccination 2 . Healthy assess medical history physical examination 3 . Parent ( ) /guardian ( ) willing let infant follow national Philippine childhood vaccination programme schedule , addition let infant receive trial vaccine 4 . Parent ( ) /guardian ( ) properly inform trial sign informed consent form 5 . Parent ( ) /guardian ( ) grant access infant 's trial relate medical record 6 . Parent ( ) /guardian ( ) likely comply trial procedure 1 . Vaccinated polio vaccine trial vaccine , prior inclusion plan trial 2 . OPV vaccination know exposure poliovirus ( wild vaccine derive ) household ( live together ) within 3 month prior inclusion plan trial 3 . Low birth weight ( &lt; 2,500 g ) 4 . Known suspected immunodeficiency ( e.g . leukaemia , lymphoma ) family history congenital hereditary immunodeficiency . HIV infection exclusion criterion 5 . Severe uncontrolled chronic ( e.g . neurologic , pulmonary , gastrointestinal , hepatic , renal endocrine ) disease 6 . Known suspected allergy vaccine constituent ( e.g . hypersensitivity formaldehyde , aluminium 2phenoxyethanol ) 7 . Uncontrolled coagulopathy blood disorder contraindicate intramuscular injection blood sample 8 . Treatment product likely modify immune response ( e.g . blood product immunoglobulin ) prior inclusion plan trial 9 . Participating another clinical trial 10 . Not suitable inclusion opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>